Page 21 of 22

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

BMJ Open

ADMINISTRATIVE INFORMATION Title: Identification 1a Identify the report as a protocol of a systematic review p.1 Update 1b If the protocol is for an update of a previous systematic review, identify as such Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registry Authors:		
Identification 1		
Update 1b If the protocol is for an update of a previous systematic review, identify as such Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registr		
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registr		
	ration number p.3	
Authors:		
Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; procorresponding author p.1	rovide physical mailing address of	
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the rev	iew p.11	
Amendments 4 If the protocol represents an amendment of a previously completed or published otherwise, state plan for documenting important protocol amendments NA	d protocol, identify as such and list changes;	
Support:		
Sources 5a Indicate sources of financial or other support for the review p.11	Indicate sources of financial or other support for the review p.11	
Sponsor 5b Provide name for the review funder and/or sponsor NA	Provide name for the review funder and/or sponsor NA	
Role of sponsor or funder 5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing	ng the protocol NA	
INTRODUCTION		
Rationale 6 Describe the rationale for the review in the context of what is already known p.	.4	
Objectives 7 Provide an explicit statement of the question(s) the review will address with reform comparators, and outcomes (PICO) p.5	ference to participants, interventions,	
METHODS	•	
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time franconsidered, language, publication status) to be used as criteria for eligibility for		
Information sources 9 Describe all intended information sources (such as electronic databases, contact grey literature sources) with planned dates of coverage p.6	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage p.6	
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, in repeated p.6 and supplemental file	ncluding planned limits, such that it could be	
Study records:		
Data management 11a Describe the mechanism(s) that will be used to manage records and data through	ghout the review p.6	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 22 of 22

BMJ Open

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) p.6
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators p.6
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications p.6-7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale p.7
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis p.8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised p.8
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall's τ) p.8
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) p.8
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned p.8
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) p.8
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) NA

^{*}It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.